产品介绍：
产品说明
包装
5, 25 mg in glass bottle
生化/生理作用
WAY-252623 (LXR623) is an orally available, potent and highly selective Liver X receptors (LXRs) agonist that significantly reduced total and LDL-cholesterol. WAY-252623 reduces lesion progression in the murine LDLR(-/-) atherosclerosis model.
其他说明
This compound was developed by Pfizer for Lipid Signaling research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.
To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
法律信息
Sold for research purposes under agreement from Pfizer Inc.
Pfizer is a registered trademark of Pfizer, Inc.
基本信息
| 经验(实验)分子式 | C21H12ClF5N2 |
| 分子量 | 422.78 |
产品性质
| 质量水平 | 100 |
| 测定 | ≥98% (HPLC) |
| 形式 | powder |
| manufacturer/tradename | Pfizer® |
| 颜色 | white to beige |
| 溶解性 | DMSO: 20 mg/mL, clear |
| 创始人 | Pfizer |
| 储存温度 | room temp |
安全信息
| 象形图 |  |
| 警示用语： | Danger |
| 危险声明 | H301 |
| 预防措施声明 | P301 + P310 |
| 危险分类 | Acute Tox. 3 Oral |
| 储存分类代码 | 6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects |
| WGK | WGK 3 |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |
